AlphaBrain logo
AlphaBrain
Galapagos N.V.

Galapagos N.V.

GLPG

$27.98

Updated: 22/09/2026, 15:05:33

Market Cap
$1.84B
Sector
Healthcare
Industry
Biotechnology
Country
BE
Stock valuation chart
One-year closing share-price history for GLPG
Company Profile

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

USD
NASDAQ
CEO: Henry O. Gosebruch
Employees: 452
https://lakefrontbio.com
Asset Summaries
Latest generated summaries for GLPG

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for GLPG.
Share price
$27.98
Market cap
$1.84B
Exchange
NASDAQ
Currency
USD
CEO
Henry O. Gosebruch
Employees
452
IPO date
27/02/2012
Beta
0.3
Last dividend
$0.00
Day range
$27.50 – $28.09
52-week range
$24.74 – $37.78
1-day performance
1.71%
1-year performance
13.10%
Current drawdown (1Y)
-25.94%
CIK
0001421876
CUSIP
36315X101
ISIN
US36315X1019
Created
07/12/2025, 04:15:24
Last update
22/09/2026, 15:05:33

Track Galapagos N.V. with an AI analyst

See which prediction-market events move GLPG, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to GLPG from your Railway `news_articles` table.

Galapagos' Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders' Meetings 2026

GlobeNewsWire • STOCK • 28/04/2026, 18:01:00

Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases

GlobeNewsWire • STOCK • 23/03/2026, 19:25:00

Galapagos Receives Transparency Notification from Bank of America

GlobeNewsWire • STOCK • 17/03/2026, 18:01:00

Galapagos Receives Transparency Notifications from Bank of America

GlobeNewsWire • STOCK • 10/03/2026, 18:01:00

Galapagos Creates New Subscription Right Plan

GlobeNewsWire • STOCK • 06/03/2026, 17:01:00

Galapagos Appoints Tania Philipp as Chief Human Resources Officer

GlobeNewsWire • STOCK • 05/03/2026, 17:01:00

Galapagos Receives Transparency Notifications from Bank of America

GlobeNewsWire • STOCK • 04/03/2026, 17:01:00

Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

GlobeNewsWire • STOCK • 23/02/2026, 17:01:00

Galapagos Receives Transparency Notification from Bank of America

GlobeNewsWire • STOCK • 16/02/2026, 17:01:00